Cargando…

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

BACKGROUND: Real-world data regarding anti-tumor necrosis factor alpha (anti-TNFα) biologic therapy use in psoriatic arthritis (PsA) are limited; therefore, we described treatment patterns and costs of anti-TNFα therapy in PsA patients in the United States. METHODS: PsA patients (N = 990) aged ≥18 y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmer, Jacqueline B., Li, Yunfeng, Herrera, Vivian, Liao, Minlei, Tran, Melody, Ozturk, Zafer E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908678/ https://www.ncbi.nlm.nih.gov/pubmed/27301458 http://dx.doi.org/10.1186/s12891-016-1102-z

Ejemplares similares

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control
por: Furst, Daniel E., et al.
Publicado: (2017)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
por: Wu, Jashin J., et al.
Publicado: (2020)

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection
por: Atteno, Mariangela, et al.
Publicado: (2014)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Treating psoriatic arthritis: how effective are TNF antagonists?
por: Gottlieb, Alice B, et al.
Publicado: (2004)

Effects of TNF-α inhibition versus secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis
por: Elliott, Ashley, et al.
Publicado: (2023)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

TNF polymorphisms are associated with the development of joint erosions in psoriatic arthritis
por: Kane, D, et al.
Publicado: (2003)

TCD4(pos) lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2017)

Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database
por: Walsh, Jessica A., et al.
Publicado: (2018)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)

Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis
por: Pirowska, Magdalena M., et al.
Publicado: (2015)

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
por: Makos, Anaïs, et al.
Publicado: (2022)

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?
por: Curry, Philippa D. K., et al.
Publicado: (2022)

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

TNF-α Activating Osteoclasts in Patients with Psoriatic Arthritis Enhances the Recruitment of Osteoclast Precursors: A Plausible Role of WNT5A-MCP-1 in Osteoclast Engagement in Psoriatic Arthritis
por: Lin, Shang-Hung, et al.
Publicado: (2022)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Brenner, Philip, et al.
Publicado: (2020)

Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis
por: Jin, Yinzhu, et al.
Publicado: (2021)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
por: Raciborski, Filip, et al.
Publicado: (2016)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2010)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2017)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
por: Cordiali-Fei, Paola, et al.
Publicado: (2006)

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
por: Fabbroni, Marta, et al.
Publicado: (2014)

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs
por: Murage, Mwangi J, et al.
Publicado: (2022)

Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF-α Treatment
por: Benhadou, Farida, et al.
Publicado: (2021)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen Minde, et al.
Publicado: (2018)

TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy
por: Guis, Sandrine, et al.
Publicado: (2016)

Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy
por: Anghel, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t1thbnheck862flpk5eebstckt